Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Menter, Alan
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. [electronic resource] - International journal of dermatology Jun 2007 - 637-48 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
0011-9059
10.1111/j.1365-4632.2007.03158.x doi
Adolescent
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Dermatologic Agents--adverse effects
Drug Administration Schedule
Female
Humans
Injections, Subcutaneous
Male
Middle Aged
PUVA Therapy
Psoriasis--drug therapy
Secondary Prevention
Severity of Illness Index
Treatment Outcome
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. [electronic resource] - International journal of dermatology Jun 2007 - 637-48 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
0011-9059
10.1111/j.1365-4632.2007.03158.x doi
Adolescent
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized
Dermatologic Agents--adverse effects
Drug Administration Schedule
Female
Humans
Injections, Subcutaneous
Male
Middle Aged
PUVA Therapy
Psoriasis--drug therapy
Secondary Prevention
Severity of Illness Index
Treatment Outcome